# Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Advanced Extrapulmonary Neuroendocrine Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05058651

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.